Champions Oncology Inc CSBR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Champions Oncology Reports Revenue of $15.2 Million
-
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
-
Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging
-
Champions Oncology Reports Record Annual Revenue of $59 Million
-
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
Trading Information
- Previous Close Price
- $4.88
- Day Range
- $4.92–5.07
- 52-Week Range
- $4.59–8.31
- Bid/Ask
- $2.02 / $8.06
- Shares Outstanding
- 13.92M
- Market Cap
- $68.76M
- Volume/Avg
- 3,555 / 11,018
Key Statistics
- Price/Earnings (Normalized)
- 205.29
- Price/Sales
- 1.13
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 214
Valuation
|
Metric
|
CSBR
|
|---|---|
Price/Earnings (Normalized) | 205.29 |
Price/Book Value | 17.66 |
Price/Sales | 1.13 |
Price/Cash Flow | 19.67 |
Price/Earnings
CSBR
Financial Strength
|
Metric
|
CSBR
|
|---|---|
Quick Ratio | 0.96 |
Current Ratio | 1.03 |
Interest Coverage | — |
Quick Ratio
CSBR
Profitability
|
Metric
|
CSBR
|
|---|---|
Return on Assets (Normalized) | 1.19% |
Return on Equity (Normalized) | 8.97% |
Return on Invested Capital (Normalized) | 3.44% |
Return on Assets
CSBR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!@<H#y | LOCK|^tpn | $128B | |||
| Moderna Inc
MRNA
| LOCK|#%B#VzB | LOCK|DN | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|c!^%<t | LOCK|^Z$s | $76B | |||
| argenx SE ADR
ARGX
| LOCK|K$FkrvT | LOCK|T% | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|gpWbd^$ | LOCK|@c! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$yNxSk | LOCK|@PF< | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&DSt?&@! | LOCK|gBcg | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|N?<GBv% | LOCK|<s | $24B | |||
| Incyte Corp
INCY
| LOCK|c%cDFm | LOCK|jVx | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|F%cTn?F | LOCK|z#N | $15B |
United States